PB1781: THE APPLICATION OF CF-DNA FOR NGS MRD STUDIES IN PATIENTS WITH LMA IMPROVES THE SENSITIVITY OF THE METHOD WITH RESPECT TO CTC.

• Noemí Álvarez Sánchez-Redondo,
• Alejandro Martin,
• Sara Dorado,
• Laura Rufián,
• Margarita Rodriguez,
• Yanira Heredia,
• Maria Calbacho Robles,
• Maria Teresa Cedena Romero,
• Joaquín Martinez-Lopez,
• Santiago Barrio,
• Rosa Ayala Diaz

Affiliations

Noemí Álvarez Sánchez-Redondo

1 Department of Translational Hematology,, Research Institute Hospital 12 de Octubre (i+12), Hematological Malignancies Clinical Research Unit H120-CNIO, CIBERONC,

Alejandro Martin

2 Altum Sequencing Co., Madrid, Spain

Sara Dorado

3 Computer Science and Engineering Department. Carlos III University, Madrid

Laura Rufián

1 Department of Translational Hematology,, Research Institute Hospital 12 de Octubre (i+12), Hematological Malignancies Clinical Research Unit H120-CNIO, CIBERONC,

Margarita Rodriguez

1 Department of Translational Hematology,, Research Institute Hospital 12 de Octubre (i+12), Hematological Malignancies Clinical Research Unit H120-CNIO, CIBERONC,

Yanira Heredia

4 Altum Sequencing Co., Madrid, Spain.

Maria Calbacho Robles

5 Department of Translational Hematology,, Research Institute Hospital 12 de Octubre (i+12), Hematological Malignancies Clinical Research Unit H120-CNIO, CIBERONC,

Maria Teresa Cedena Romero

5 Department of Translational Hematology,, Research Institute Hospital 12 de Octubre (i+12), Hematological Malignancies Clinical Research Unit H120-CNIO, CIBERONC,

Joaquín Martinez-Lopez

5 Department of Translational Hematology,, Research Institute Hospital 12 de Octubre (i+12), Hematological Malignancies Clinical Research Unit H120-CNIO, CIBERONC,

Santiago Barrio

4 Altum Sequencing Co., Madrid, Spain.

Rosa Ayala Diaz

5 Department of Translational Hematology,, Research Institute Hospital 12 de Octubre (i+12), Hematological Malignancies Clinical Research Unit H120-CNIO, CIBERONC,